Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...

The 2023 revenues had benefited from a 30 million euros milestone payment from Boehringer Ingelheim associated with survodutide and $10 million milestone payment from Sanofi associated with ...

Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...

Savant Capital LLC raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 24.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease <li /> New detailed data from ...

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...